Coronary Flow Reserve Changes After Semaglutide Treatment

Ekrem Bilal Karaayvaz

Status: Completed

Conditions: Obesity &Amp; Overweight; The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients

Study type: Observational

Funder types: Other

Identifiers

NCT07190144

IstanbulU-EBKaraayvaz-2

Details and patient eligibility

About

The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is:

Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients?

Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.

Enrollment: 122 patients

Sex: All

Ages: 28 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were planned to start semaglutide.

Exclusion criteria

• Ischemic heart disease
• Previous stent implantation or coronary bypass
• Heart failure
• Cardiomyopathies
• Inflammatory diseases
• Autoimmune rheumatic disease
• Chronic liver and renal insufficiency

Trial design

122 participants in 2 patient groups

Non-diabetic patients

Description:

Non-diabetic patients who have planned to given semaglutide by an endocrinology specialist, mostly to give weight, were performed CFR with echocardiography before and 3 months after the treatment.

Diabetic patients

Description:

Diabetic patients, who were planned to start semaglutide by an endocrinology specialist and were otherwise has same demographic data as non-diabetic patients, were performed CFR with echocardiography before and 3 months after the treatment